/
We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by e stablishing a new class of medicines that engage intracellular targets that have long been considered inaccessible . Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited …
The business is unprofitable at the operating level (-621.13% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 87.9% YoY. Margins deteriorated 643.4pp alongside, both lines moving the wrong way.
ROIC dropped from 11.56% to -29.53%, capital efficiency is deteriorating. Negative free cash flow of -$130M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$6M
▼ -87.9% YoY
Net Income (TTM)
-$166M
▼ -319.0% YoY
Op. Margin
-3109.29%
▼ -643.4pp YoY
ROIC
-37.46%
▼ -41.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$132M
▼ -189.7% YoY
Op. Cash Flow (TTM)
-$132M
▼ -209.2% YoY
Net Debt
-$27M
Net Cash Position
Cash & Equiv.
$76M
Continue Research